[go: up one dir, main page]

WO2000050595A3 - Molecules d'acide nucleique associees aux melanomes et aux tumeurs de la thyroide - Google Patents

Molecules d'acide nucleique associees aux melanomes et aux tumeurs de la thyroide Download PDF

Info

Publication number
WO2000050595A3
WO2000050595A3 PCT/US2000/004929 US0004929W WO0050595A3 WO 2000050595 A3 WO2000050595 A3 WO 2000050595A3 US 0004929 W US0004929 W US 0004929W WO 0050595 A3 WO0050595 A3 WO 0050595A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
melanoma
thyroid tumors
molecules associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/004929
Other languages
English (en)
Other versions
WO2000050595A2 (fr
Inventor
Ivan Gout
Nikolay Rodnin
Valery Filonenko
Genadiy Matsuka
Matthew Scanlan
Lloyd Old
Boris Bilynsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU32462/00A priority Critical patent/AU3246200A/en
Publication of WO2000050595A2 publication Critical patent/WO2000050595A2/fr
Publication of WO2000050595A3 publication Critical patent/WO2000050595A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des molécules d'acide nucléique isolées associées à des mélanomes ou des tumeurs de la thyroïde. L'invention traite également de compositions dérivées de ces molécules. La présente invention concerne aussi des procédés permettant de diagnostiquer et de traiter des mélanomes, des tumeurs de la thyroïde et d'autres conditions pathologiques liées comme le cancer du rectum, le cancer du poumon, le cancer du sein et le cancer du colon, en utilisant des molécules d'acides nucléiques et des compositions de ce type.
PCT/US2000/004929 1999-02-25 2000-02-25 Molecules d'acide nucleique associees aux melanomes et aux tumeurs de la thyroide Ceased WO2000050595A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32462/00A AU3246200A (en) 1999-02-25 2000-02-25 Nucleic acid molecules associated with melanoma and thyroid tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25741799A 1999-02-25 1999-02-25
US09/257,417 1999-02-25

Publications (2)

Publication Number Publication Date
WO2000050595A2 WO2000050595A2 (fr) 2000-08-31
WO2000050595A3 true WO2000050595A3 (fr) 2001-06-21

Family

ID=22976239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004929 Ceased WO2000050595A2 (fr) 1999-02-25 2000-02-25 Molecules d'acide nucleique associees aux melanomes et aux tumeurs de la thyroide

Country Status (2)

Country Link
AU (1) AU3246200A (fr)
WO (1) WO2000050595A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161374A (ja) * 1999-12-13 2001-06-19 Akihiro Abe ポリヌクレオチド、ポリペプチド、ガン治療薬及びワクチン
EP1266225A2 (fr) * 2000-03-20 2002-12-18 Oxford GlycoSciences (UK) Limited Diagnostique et traitement du cancer du sein
EP1918386B9 (fr) 2002-03-13 2012-08-08 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
EP1570080A4 (fr) 2002-11-15 2006-03-01 Genomic Health Inc Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ATE412779T1 (de) 2003-02-20 2008-11-15 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
CA2530738C (fr) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction de probabilite de la recurrence d'un cancer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
KR20070000438A (ko) 2003-12-23 2007-01-02 게노믹 헬쓰, 인코포레이티드 단편화 ｒｎａ의 범용적 증폭
EP2163650B1 (fr) 2004-04-09 2015-08-05 Genomic Health, Inc. Marqueurs d'expression de gènes pour prédire une réponse à la chimiothérapie
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US7930104B2 (en) 2004-11-05 2011-04-19 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006052731A2 (fr) 2004-11-05 2006-05-18 Genomic Health, Inc. Indicateurs moleculaires de pronostic de cancer du sein et prediction de reponse de traitement
AU2009203562A1 (en) * 2008-01-07 2009-07-16 Patrys Limited BARB4 target which comprises TATA-binding protein-associated factor 15, antibody designated BARB4, BARB4 related antibodies, and methods of making and using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196307A (en) * 1988-03-29 1993-03-23 The Johns Hopkins University Cloned human centromere autoantigen
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1999004040A1 (fr) * 1997-07-15 1999-01-28 Ludwig Institute For Cancer Research Procedes de diagnostic et de traitement du cancer, et procedes d'identification de marqueurs pathogenes dans un echantillon de cellules normales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196307A (en) * 1988-03-29 1993-03-23 The Johns Hopkins University Cloned human centromere autoantigen
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1999004040A1 (fr) * 1997-07-15 1999-01-28 Ludwig Institute For Cancer Research Procedes de diagnostic et de traitement du cancer, et procedes d'identification de marqueurs pathogenes dans un echantillon de cellules normales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STRAUSBERG ET AL.: "National cancer institute, cancer genome anatomy project (CGAP)", EMBL DATABASE ACC. NO: AI239958, 5 November 1998 (1998-11-05), XP002141437 *
SULLIVAN: "Human hCENP-B gene for centromere autoantigen B", EMBL DATABASE ACC NO: X55039, 2 August 1991 (1991-08-02), XP002141627 *
TÜRECI ET AL.: "The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40", CANCER RESEARCH, vol. 56, 15 October 1996 (1996-10-15), pages 4766 - 4772, XP002141438 *

Also Published As

Publication number Publication date
WO2000050595A2 (fr) 2000-08-31
AU3246200A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
WO2000050595A3 (fr) Molecules d'acide nucleique associees aux melanomes et aux tumeurs de la thyroide
WO2006105486A3 (fr) Nouveau gene suppresseur de tumeur, et compositions et procedes de fabrication et d'utilisation de ce gene
WO2003050243A3 (fr) Nouveaux genes, nouvelles compositions, nouveaux kits et nouveaux procedes d'identification, d'evaluation, de prevention et de therapie du cancer du colon
WO2006012646A3 (fr) Marqueurs de cancers amacr
GR3023560T3 (en) Analytical tracers for cancer, particularly malignant breast cancer
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2003021227A3 (fr) Methodes et compositions utiles pour diagnostiquer, determiner un stade, et traiter des cancers et des tumeurs
WO1999057565A3 (fr) Procedes servant a diagnostiquer et a evaluer le cancer
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
WO2006119365A3 (fr) Compositions et procedes destines au diagnostic et au traitement du cancer
WO2007009755A8 (fr) Compositions et methodes de diagnostic du cancer contenant des marqueurs pantumoraux
WO2004060302A3 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
EP2431743A3 (fr) Glycanes spécifiques du cancer et leur utilisation
WO2001036685A3 (fr) Expression differentielle de genes dans le cancer
WO2003000012A3 (fr) Compositions, necessaires et methodes destines a l'identification, a l'evaluation, a la prevention et au traitement des cancers du sein et de l'ovaire
WO2001052904A3 (fr) Compositions renfermant des oligonucleotides antisens diriges contre le vegf et methodes associees
WO2004044160A3 (fr) Compositions d'arn a interference avec muc1 et procedes derives
WO2009153774A3 (fr) Compositions et procédés pour le pronostic du cancer des ovaires
WO2002064839A3 (fr) Gene amplifie de l'hepsine associee au cancer
WO2004031402A3 (fr) Profil de methylation du cancer
WO2007056049A3 (fr) Profilage moleculaire de cancer
WO1999028460A3 (fr) Molecules ayant une interaction avec l'apoptine
FR2875601B1 (fr) Vimentine phosphorylee comme marqueur de l'agressivite et/ou l'invasivite des tumeurs
EP0943620A3 (fr) Dérivés de l'acide bétulinique pour inhibition de la croissance des cancers
WO2002092837A3 (fr) Molecule d'acide nucleique associee a l'immunodetection et a l'immunotherapie du cancer de la prostate et d'un melanome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase